Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

The Lancet Infectious Diseases

Volumn 15, Issue 10, 2015, Pages 1167-1174

  Koh, Christopher ^a   Canini, Laetitia ^b,c   Dahari, Harel ^b,d   Zhao, Xiongce ^a   Uprichard, Susan L ^b   Haynes Williams, Vanessa ^a   Winters, Mark A ^e   Subramanya, Gitanjali ^b   Cooper, Stewart L ^f   Pinto, Peter ^g   Wolff, Erin F ^h   Bishop, Rachel ^a,i   Ai Thanda Han, Ma ^a   Cotler, Scott J ^b   Kleiner, David E ^g   Keskin, Onur ^a,j   Idilman, Ramazan ^a,j   Yurdaydin, Cihan ^a,j   Glenn, Jeffrey S ^e   Heller, Theo ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ NATIONAL EYE INSTITUTE   (United States)

^j ANKARA UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; LONAFARNIB; PLACEBO; VIRUS RNA; ANTIVIRUS AGENT; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DIARRHEA; DISEASE DURATION; DIZZINESS; DNA REPLICATION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRENYLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCROTAL PAIN; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; BLOOD; CHEMISTRY; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PLASMA; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PLACEBOS; PLASMA; PRENYLATION; PYRIDINES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84942199484     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00074-2     Document Type: Article

References (27)

1. Glenn JS, Marsters JC, Greenberg HB Use of a prenylation inhibitor as a novel antiviral agent. J Virol 1998, 72:9303-9306.
2. Gudima S, Chang J, Moraleda G, Azvolinsky A, Taylor J Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA. J Virol 2002, 76:3709-3719.
3. Hughes SA, Wedemeyer H, Harrison PM Hepatitis delta virus. Lancet 2011, 378:73-85.
4. Rizzetto M, Ponzetto A, Forzani I Hepatitis delta virus as a global health problem. Vaccine 1990, 8:S10-S14.
5. Wedemeyer H, Manns MP Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010, 7:31-40.
6. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977, 18:997-1003.
7. Radjef N, Gordien E, Ivaniushina V, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004, 78:2537-2544.
8. Makuwa M, Caron M, Souquiere S, Malonga-Mouelet G, Mahe A, Kazanji M Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol 2008, 46:754-756.
9. Govindarajan S, Kanel GC, Peters RL Prevalence of delta-antibody among chronic hepatitis B virus infected patients in the Los Angeles area: its correlation with liver biopsy diagnosis. Gastroenterology 1983, 85:160-162.
10. Colombo M, Cambieri R, Rumi MG, Ronchi G, Del Ninno E, De Franchis R Long-term delta superinfection in hepatitis B surface antigen carriers and its relationship to the course of chronic hepatitis. Gastroenterology 1983, 85:235-239.
11. Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol 2013, 59:949-956.
12. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000, 46:420-426.
13. Ji J, Sundquist K, Sundquist J A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst 2012, 104:790-792.
14. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009, 136:1629-1638.
15. Lok AS, McMahon BJ Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
16. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185. European Association For The Study Of The Liver.
17. Wedemeyer H, Yurdaydin C, Ernst S, et al. 96 weeks of pegylated-interferon-alfa-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. Hepatology 2013, 58:222A-223A.
18. Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther 2014, 40:93-104.
19. Einav S, Glenn JS Prenylation inhibitors: a novel class of antiviral agents. J Antimicrob Chemother 2003, 52:883-886.
20. Bordier BB, Marion PL, Ohashi K, et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 2002, 76:10465-10472.
21. Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003, 112:407-414.
22. Guedj J, Rotman Y, Cotler SJ, et al. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology 2014, 60:1902-1910.
23. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008, 15:314-321.
24. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006, 44:728-735.
25. Feldman EJ, Cortes J, DeAngelo DJ, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 2008, 22:1707-1711.
26. Ravoet C, Mineur P, Robin V, et al. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol 2008, 87:881-885.
27. Gordon LB, Kleinman ME, Miller DT, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2012, 109:16666-16671.